Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Successful use of very low dose subcutaneous decitabine to treat high-risk myelofibrosis with Sweet syndrome that was refractory to 5-azacitidine.

× No keyword cloud information.

6 in total

Review 1. Novel therapies for myelofibrosis.

Authors: Brady L Stein; Francisco Cervantes; Francis Giles; Claire N Harrison; Srdan Verstovsek
Journal: Leuk Lymphoma Date: 2015-05-18

2. Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates.

Authors: Xiaorong Gu; Quteba Ebrahem; Reda Z Mahfouz; Metis Hasipek; Francis Enane; Tomas Radivoyevitch; Nicolas Rapin; Bartlomiej Przychodzen; Zhenbo Hu; Ramesh Balusu; Claudiu V Cotta; David Wald; Christian Argueta; Yosef Landesman; Maria Paola Martelli; Brunangelo Falini; Hetty Carraway; Bo T Porse; Jaroslaw Maciejewski; Babal K Jha; Yogen Saunthararajah
Journal: J Clin Invest Date: 2018-07-17 Impact factor: 14.808

Review 3. Definition and management of ruxolitinib treatment failure in myelofibrosis.

Authors: A Pardanani; A Tefferi
Journal: Blood Cancer J Date: 2014-12-12 Impact factor: 11.037

4. Severe pyoderma gangrenosum caused by myelodysplastic syndrome successfully treated with decitabine administered by a noncytotoxic regimen.

Authors: Mostafa F M Saleh; Yogen Saunthararajah
Journal: Clin Case Rep Date: 2017-10-31

Review 5. Insights Into the Pathogenesis of Sweet's Syndrome.

Authors: Michael S Heath; Alex G Ortega-Loayza
Journal: Front Immunol Date: 2019-03-12 Impact factor: 7.561

Review 6. Targeting sickle cell disease root-cause pathophysiology with small molecules.

Authors: Yogen Saunthararajah
Journal: Haematologica Date: 2019-08-08 Impact factor: 9.941

6 in total